Sin lv mediated ex vivo transduced autologous fibroblasts expressing codon-optimised col7a1    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
36Epidermolysis bullosa1

36. Epidermolysis bullosa    [ 147 clinical trials,   170 drugs,   (DrugBank: 40 drugs),   32 drug target genes,   113 drug target pathways]
Searched query = "Epidermolysis bullosa", "EBS", "JEB", "DDEB", "RDEB", "Kindler syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 147 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-004884-19-GB
(EUCTR)
24/05/201618/02/2015Gene Therapy Trial in adults with Inherited Blistering Skin DiseasePhase I study of lentiviral-mediated COL7A1 gene-modified autologous fibroblasts in adults with recessive dystrophic epidermolysis bullosa (RDEB) - LENTICOL-F Recessive Dystrophic Epidermolysis Bullosa
MedDRA version: 18.1;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: SIN LV Mediated ex vivo transduced autologous fibroblasts expressing codon-optimised COL7A1
Product Code: Not applicable
King's College LondonGuy's and St Thomas' NHS Foundation TrustNot RecruitingFemale: yes
Male: yes
10Phase 1United Kingdom